Here are the 424B prospectus supplements from Pfizer Inc. (PFE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PFE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFE filings page.
Pfizer Inc. is issuing $500 million of floating-rate notes due 2027 and $5.5 billion of fixed-rate notes maturing between 2027 and 2065. The fixed-rate tranches carry coupons of 3.875% (2027), 4.200% (2030), 4.500% (2032), 4.875% (2035), 5.600% (2055) and 5.700% (2065), with interest paid semi-annually, while the floating-rate notes pay quarterly interest at Compounded SOFR plus 0.500%. The notes are unsecured, unsubordinated obligations ranking equally with Pfizer’s other unsubordinated debt and have no sinking fund.
Pfizer expects net proceeds of approximately $5,966,010,000 after underwriting discounts, to be used for general corporate purposes, including funding the acquisition of Metsera and refinancing existing indebtedness. Fixed-rate notes are callable at Pfizer’s option (subject to make‑whole and par call features), while the floating-rate notes are not redeemable before maturity. The notes will not be listed on any securities exchange, and Pfizer highlights risks around subordination to secured and subsidiary debt, benchmark rate reform and SOFR-related volatility for the floating‑rate series.